In a breast cancer mouse model treated with low-dose cyclophosphamide combined with CSF1R inhibitors, CD4+ T cells and antigen-presenting B cells were enriched and colocalized in the TLS, inducing the durable tumor regression after combination treatment 78. This evidence concerns the gene CD4 and neoplasm.